Loading…
Loading…
MRND (IQ U.S. Mid Cap R&D Leaders ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how MRND's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MRND and 80,000+ other tickers.
This ETF is designed to offer investors an opportunity to engage with pioneering U.S. companies of medium market capitalization, particularly those distinguished by substantial investments in research and development (R&D). Under ordinary market conditions, the fund commits a minimum of 80% of its total net assets, alongside any capital borrowed for investment, to the securities that constitute its benchmark index. It operates as a non-diversified investment.
The second full week of December saw a ramp-up in activity, with 20 launches and several closures. Newcomer ETF issuer Themes ETFs alone rolled out 8 new thematic ETFs.
We have recently received three new ETFs built on the concept of R&D.
Smaller equities are following their large-cap counterparts lower this year, perhaps giving investors reason to overlook mid-cap stocks. However, that may be the wrong course of action.
The U.S. exchange-traded fund (ETF) industry had quite a year in 2021 – due in part to the 445 new ETFs that launched, 44% more than did in 2020. U.S. ETFs ended the year with record assets of $7.21 trillion, 31.9% higher 2020.
New York Life's ETF brand is targeting companies that spend big on research.